To address the in vivo efficacy of the EGFR phenotype conversion, we generated1:1 mixed EGFR-low and EGFR-high cells xenografts and the tumor-bearing mice were pre-treated for 24 h with either vehicle or panobinostat (5 mg/kg). This evidence concerns the gene EGFR and neoplasm.